Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer.

[1]  Deborah B. Thompson,et al.  Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network , 1997, The Journal of pathology.

[2]  M. Skobe,et al.  Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[4]  A. Weaver,et al.  Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. , 2001, The Journal of urology.

[5]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[6]  Ronglai Shen,et al.  Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. , 2002, The American journal of pathology.

[7]  I. Leav,et al.  Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. , 2003, Human pathology.

[8]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Rajiv Dhir,et al.  Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors , 2005, BMC Cancer.

[10]  J. Jones,et al.  Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. , 2004, Urology.

[11]  D. Landsittel,et al.  Early identification of individuals with prostate cancer in negative biopsies. , 2004, The Journal of urology.

[12]  Vijayalakshmi Ananthanarayanan,et al.  Alpha‐methylacyl‐CoA racemase (AMACR) expression in normal prostatic glands and high‐grade prostatic intraepithelial neoplasia (HGPIN): Association with diagnosis of prostate cancer , 2005, The Prostate.

[13]  C. D. Savci-Heijink,et al.  Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer , 2007, BMC Molecular Biology.

[14]  M. Skobe,et al.  Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells. , 2006, The American journal of pathology.

[15]  Ron Shamir,et al.  Identification of functional modules using network topology and high-throughput data , 2007, BMC Systems Biology.

[16]  Daniel W Lin,et al.  Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Heldin,et al.  PDGF receptors as targets in tumor treatment. , 2007, Advances in cancer research.

[18]  J. Homsi,et al.  Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[19]  V. Kosma,et al.  Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. , 2008, Seminars in cancer biology.

[20]  C. Betsholtz,et al.  Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. , 2009, Cancer research.

[21]  A. Poustka,et al.  Molecular cancer phenotype in normal prostate tissue. , 2009, European urology.

[22]  M. Lucia,et al.  Prostate Cancer Detected by Methylated Gene Markers in Histopathologically Cancer-Negative Tissues from Men with Subsequent Positive Biopsies , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[23]  K. Butler,et al.  Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. , 2009, International journal of oncology.

[24]  P. Sorensen,et al.  The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA , 2010, BMC Biology.

[25]  C. Moreno.  The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. , 2010, The American journal of pathology.

[26]  Richard M. Karp,et al.  DEGAS: De Novo Discovery of Dysregulated Pathways in Human Diseases , 2010, PloS one.

[27]  G. Firestone,et al.  BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype , 2010, Cancer biology & therapy.

[28]  Nolwenn LeMeur,et al.  Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect , 2010, Clinical Cancer Research.

[29]  Zhenyu Jia,et al.  In silico estimates of tissue components in surgical samples based on expression profiling data. , 2010, Cancer research.

[30]  Carolyn J. Brown,et al.  The functional role of long non-coding RNA in human carcinomas , 2011, Molecular Cancer.